Fingolimod attenuates renal ischemia/reperfusion-induced acute lung injury by inhibiting inflammation and apoptosis and modulating S1P metabolism

J Int Med Res. 2021 Aug;49(8):3000605211032806. doi: 10.1177/03000605211032806.

Abstract

Objective: This study examined whether the immunomodulator fingolimod (FTY720) could alleviate renal ischemia/reperfusion (I/R)-induced lung injury and explored the potential mechanisms.

Methods: Renal I/R was established in a rat model, and FTY720 (0.5, 1, or 2 mg/kg) was injected intraperitoneally after 15 minutes of ischemia. Pro-inflammatory cytokine levels, oxidative stress, apoptosis, and the mRNA expression of the sphingosine-1-phosphate (S1P)-related signaling pathway genes sphingosine kinase-1 (SphK1) and sphingosine kinase-2 were analyzed in lung tissue.

Results: Increased pro-inflammatory cytokine levels; decreased total superoxide dismutase, catalase, and glutathione peroxidase levels; increased apoptosis; and increased S1P lyase and SphK1 expression were observed following renal I/R. FTY720 reversed renal I/R-induced changes and effectively attenuated lung injury.

Conclusion: FTY720 protected against acute lung injury in rats subjected to renal I/R by decreasing pulmonary inflammation and apoptosis, increasing oxidative stress, and modulating S1P metabolism.

Keywords: Fingolimod; acute lung injury; apoptosis; oxidative stress; pro-inflammatory cytokine; renal ischemia/reperfusion; sphingosine-1-phosphate.

MeSH terms

  • Acute Lung Injury*
  • Animals
  • Apoptosis
  • Fingolimod Hydrochloride / pharmacology
  • Inflammation / drug therapy
  • Ischemia
  • Lysophospholipids
  • Rats
  • Reperfusion
  • Reperfusion Injury* / drug therapy
  • Sphingosine

Substances

  • Lysophospholipids
  • Fingolimod Hydrochloride
  • Sphingosine